New progestogens in oral contraception

Area of Science:

• Pharmacology
• Endocrinology
• Gynecology

Background:

• Combined oral contraceptives (COCs) have evolved with reduced estrogen and progestogen doses.
• Newer progestogens in COCs are marketed for increased selectivity.
• Previous generations of COCs, particularly low-dose formulations, have a long history of safe use.

Purpose of the Study:

• To review the clinical efficacy of new COCs.
• To compare new COCs with older formulations containing levonorgestrel or norethisterone.
• To evaluate the pharmacological effects of new COCs on metabolic, hematological, and hormonal parameters.

Main Methods:

• Review of clinical efficacy data for new COCs.
• Pharmacological assessment of effects on carbohydrate and lipid metabolism.
• Analysis of impact on hematological factors, pituitary-ovarian function, and serum protein/androgen levels.

Main Results:

• Newer COCs show pharmacological improvements over older low-dose formulations.
• Newer COCs are preferable to high-dose formulations based on pharmacological evidence.
• Older low-dose COCs exhibit a low incidence of adverse effects despite prolonged use.

Conclusions:

• Newer combined oral contraceptives represent an advancement over older formulations.
• The clinical acceptance and increasing market share of new COCs indicate positive reception.
• Both older low-dose and newer COCs have established roles, with newer options offering pharmacological benefits.